FranciscoJoseRicartMD

Physician

Dr. Ricart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Dr. Francisco Ricart is a psychiatrist in Coral Gables, FL and is affiliated with Mercy Hospital Miami. He received his medical degree from Universidad Autonoma de Santo Domingo and has been in practice 27 years. He also speaks multiple languages, including Spanish. He is experienced in classical psychoanalysis, dementa, and hiv.

The Psychoanalytic InstitutePsychoanalytic training, Psychoanalysis, 1997 - 2002
Icahn School of Medicine at Mount SinaiFellowship, HIV Psychiatry, 2000 - 2001
Westchester Medical CenterResidency, Psychiatry, 1996 - 2000
Universidad Autonoma de Santo DomingoClass of 1990
Universidad Autonoma de Santo Domingo, U.A.S.D.No degree, 1983 - 1984

Doctors of Excellence The Leading Physicians of the World, 2015
Academic Award Department of Psychiatry, New York Medical College, Mentropolitan Hospital Center, 2000
Doctor in Medicine "Cum Laude" Universidad Autonoma de Santo Domingo, 1990

PubMed

12 citations
Understanding the psychodynamics of non-adherence to medical treatment in persons with HIV infection
Francisco Ricart, Mary Ann Cohen, Cesar A. Alfonso, Rosalind G. Hoffman, Nancy Quiñones, Alan Cohen, Debbie Indyk> ;General Hospital Psychiatry. 2002 May 1

Journal Articles

Understanding the psychodynamics of non-adherence to medical treatment in persons with HIV infection
Ricart, et al, General Hospital Psychiatry, 1/1/2002

Sub PISNS318HR-3188HR (1602T0832): A phase 3, multicenter, randomized, double-blind study of a single dose of S 033188 40 mg compared with placebo or Oseltamivir 75 mg twice daily for 5 days in patients with influenza at high risk of influenza complications2017 - Present
PIE2609-G000-202. A placebo-controlled, double-blind, parallel-group, randomized, proof of concept, dose-finding study to evaluate safety, tolerability and efficacy of E2609 in subjects with mild cognitive impairment due to Alzheimer's disease (prodromal) and mild dementia due to Alzheimer's disease.2016 - Present
PI15-AVP-786-302-Amendment 2. A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-M]/quinidine sulfate [Q]) for the treatment of agitation in patients with Alzheimer's.2016 - Present
PICTP2S1502HT6. A phase 2A multicenter, randomized, double-bind, parallel group, 26 week placebo-controlled study of 50 mg and 100 mg of SUVN-502 in subjects with moderate Alzheimer's disease currently treated with donepezil hydrochloride and memantine hydrochloride.2015 - Present
Sub PIEisai BAN2401 in subjects with early Alzheimer's disease. A placebo-controlled, doubled-blind, parallel-group, Bayesian adaptive, randomization design and dose regimen finding Study to evaluate safety, tolerability and efficacy of BAN2401 in subjects with early Alzheimer's disease.2014 - 2017